anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method for the selection and production of group specific immunoglobulins to bind to specific microbes or their toxins is provided. The immunoglobulins are produced in animals and collected either in the plasma or colostrums of the animals after being challenged with a series of selected immunogens. The selected immunoglobulins are packaged into products against specific groups of microbes or their toxins. These packages are delivered to animals including humans. These products could be used as passive protectants. The packages could be developed into products to protect animals or humans against diseases until vaccines can be effectively administered.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to ASPARLAS in the studies described below with the incidence of antibodies in other studies or to other asparaginase products may be misleading.

Immunogenicity was assessed using enzyme linked immunosorbent assays (ELISA) in Study DFCI 11-001. Of 98 evaluable patients treated with ASPARLAS, 15 (15%) patients developed new or an increased titer of anti-drug antibodies (ADA) during treatment; 14 of these 15 patients were positive for anti-PEG antibodies. The presence of ADA correlated with the occurrence of hypersensitivity reactions [see Adverse Reactions (6.1)]. There is insufficient information to determine whether the development of antibodies is associated with altered pharmacokinetics (i.e., loss of asparaginase activity).

Specific Populations

The impact of renal and hepatic impairment on the PK of calaspargase pegol-mknl is unknown.
In the control arm patient and physician will decide which treatment to choose. Patients will be either treated with ocrelizumab according to the SmPC (600 mg every 6 months continuously) or with alemtuzumab according to the SmPC (12 mg/day for 5 consecutive days and again after 365 days for 3 days).
FIELD: cosmetology. SUBSTANCE: cream has simple and complex lipids from animals, cacao oil, glycerol, emulsifier, amino acids, mineral salts, vitamins, preserving agent and water. Cream is prepared by preliminary melting at 40-45 C, then emulsifier and cacao oil are added, mixture is stirred for 30-40 min, emulsified for 30-40 min, and then water, amino acids, vitamins, organic salts and glycerol are added. Temperature of mixture is increased up to 20-25 C, prepared mixture is emulsified for 5-10 min, temperature is decreased up to 5-10 C, and preserving agent and perfume are added. EFFECT: enhanced quality of cream. 3 cl
FIELD: medicine. SUBSTANCE: proposed method of determination of degree of risk of lead intoxication provides for investigation of content of lead in day's portion of urine and for additional homeocentric biological action on examined person with subsequent determination of content of lead in day's portion of urine. If increase of content of lead exceeds 10% relative to initial content low degree of risk of lead intoxication is determined. If given factor increases or decreases by not more than 10% or if there is no changes of it moderate degree of risk of lead intoxication is defined. Decrease of this factor by more than 10% defines high degree of risk of lead intoxication. EFFECT: improved authenticity of method. 8 tbl
BACKGROUND: Brady-arrhythmia requiring pacemaker implantation remains one of the Fontan-specific complications before and after total cavopulmonary connection.
METHODS: A retrospective analysis of 620 patients who underwent total cavopulmonary connection between 1994 and 2021 was performed to evaluate the incidence of brady-arrhythmia and the outcomes after pacemaker implantation. Factors associated with the onset of brady-arrhythmia were identified.
RESULTS: A total of 52 patients presented with brady-arrhythmia and required pacemaker implantation. Diagnosis included 16 sinus node dysfunctions, 29 atrioventricular blocks, and 7 junctional escape rhythms. Pacemaker implantation was performed before total cavopulmonary connection (n = 16), concomitant with total cavopulmonary connection (n = 8), or after total cavopulmonary connection (n = 28, median 1.8 years post-operatively). Freedom from pacemaker implantation following total cavopulmonary connection at 10 years was 92%. Twelve patients needed revision of electrodes due to lead dysfunction (n = 9), infections (n = 2), or dislocation (n = 1). Lead energy thresholds were stable, and freedom from pacemaker lead revision at 10 years after total cavopulmonary connection was 78%. Congenitally corrected transposition of the great arteries (odds ratio: 6.6, confidence interval: 2.0-21.5, p = 0.002) was identified as a factor associated with pacemaker implantation before total cavopulmonary connection. Pacemaker rhythms for Fontan circulation were not a risk factor for survival (p = 0.226), protein-losing enteropathy/plastic bronchitis (p = 0.973), or thromboembolic complications (p = 0.424).
CONCLUSIONS: In our cohort of patients following total cavopulmonary connection, freedom from pacemaker implantation at 10 years was 92% and stable atrial and ventricular lead energy thresholds were observed. Congenitally corrected transposition of the great arteries was at increased risk for pacemaker implantation before total cavopulmonary connection. Having a pacemaker in the Fontan circulation had no adverse effect on survival, protein-losing enteropathy/plastic bronchitis, or thromboembolic complications.
1. Adhere to strict aseptic procedures during preparation.
  2. Allow the DEFINITY vial to warm to room temperature before starting the activation procedure.
  3. Activate DEFINITY by shaking the vial for 45 seconds using a VIALMIX device or VIALMIX RFID device.  
Note: Use only the drug activated in a properly functioning VIALMIX or VIALMIX RFID for a full 45 second activation cycle. Do not reactivate the vial if VIALMIX or VIALMIX RFID did not properly activate the vial. Never reactivate a successfully activated DEFINITY vial (see step 4). Refer to the VIALMIX or VIALMIX RFID User's Guide for illustrations of the activation procedure and a properly functioning VIALMIX or VIALMIX RFID. 
  4. Activated DEFINITY appears as a homogeneous milky white suspension with a presence of foam/bubbles. Use immediately after activation. If the product is not used within 5 minutes of activation, resuspend the microspheres by 10 seconds of hand agitation by inverting the vial before the product is withdrawn in a syringe.

  5. The activated DEFINITY may be used for up to 12 hours from the time of activation, but only after the microspheres are resuspended by hand agitation for 10 seconds. Store the activated DEFINITY at room temperature 20° to 25°C (68° to 77°F) in the original product vial.
  6. Invert the vial and withdraw the activated homogeneous milky white suspension using the Intellipin (Dispensing Pin), the PINSYNC (Vented Vial Adapter 13mm), or 18 gauge to 20 gauge syringe needle from the middle of the liquid. Do not inject air into the DEFINITY Vial.
  7. Use the product immediately after its withdrawal from the vial; do not allow the product to stand in the syringe.
  8. For infusion dosing in adult patients, dilute 1.3 mL of activated DEFINITY in 50 mL of preservative-free 0.9% Sodium Chloride Injection, USP.
  9. Parenteral drug products should be inspected visually for foreign particulate matter and discoloration prior to administration, whenever solution and container permit.
INTRODUCTION: Mantle cell lymphoma (MCL) is an uncommon non-Hodgkin lymphoma that is generally considered incurable. Covalent BTK inhibitors (cBTKi) are the cornerstone of treatment for relapsed or refractory (R/R) MCL, but treatment options are limited and prognosis is poor after cBTKi failure. Pirtobrutinib is a non-covalent BTK inhibitor that has demonstrated excellent efficacy and safety and represents an important new treatment in the evolving treatment landscape of R/R MCL.
AREAS COVERED: This review will provide an overview of the therapeutic landscape of R/R MCL, characteristics of pirtobrutinib, and efficacy and safety data of pirtobrutinib in R/R MCL from pivotal clinical trials. PubMed and major hematology conference proceedings were searched to identify relevant studies involving pirtobrutinib.
EXPERT OPINION: For patients with R/R MCL that has progressed after treatment with cBTKi, pirtobrutinib is an important and efficacious treatment that confers favorable outcomes. In the post-cBTKi setting, when chimeric antigen receptor (CAR) T-cell therapy is not available or feasible, pirtobrutinib is the preferred treatment for R/R MCL. How to sequence or combine pirtobrutinib with CAR T-cell therapy and other available or emerging therapies requires further investigation. Future studies should also explore the role of pirtobrutinib in earlier lines of therapy for MCL.
Many studies have shown that hematocrit (HCT) levels are associated with cerebrovascular disease, cardiovascular disease (CVD), peripheral vascular disease, as well as all-cause mortality. Twin studies have shown that HCT variation is largely determined by genetic factors with heritability estimated as 40% - 65%. So far, no linkage analysis in humans between HCT and DNA markers have been reported. The purpose of this protocol is to identify chromosome regions that contain quantitative trait loci (QTL) involved in controlling HCT levels. In the Framingham Study, a 10cM genome scan (about 400 markers) has been conducted in 330 families. HCT was measured in the original cohort and Framingham offspring. These data provide us the opportunity to undertake linkage analyses using variance component method to map quantitative trait loci (QTL) of HCT.
OBJECTIVE: This study aims to evaluate a novel prone position ventilation device designed to enhance patient safety, improve comfort, and reduce adverse events, facilitating prolonged tolerance in critically ill patients.
METHODS: A randomized controlled trial was conducted on 60 critically ill patients from January 2020 to June 2023. Of which, one self-discharged during treatment and another was terminated due to decreased oxygenation, leaving an effective sample of 58 patients. Patients were allocated to either a control group receiving traditional prone positioning aids (ordinary sponge pads and pillows) or an intervention group using a newly developed adjustable prone positioning device. A subset of patients in each group also received life support technologies such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). We assessed prone position ventilation tolerance, oxygen saturation increments postintervention, duration of prone positioning, CRRT filter lifespan, and the incidence of adverse events.
RESULTS: The intervention group exhibited significantly longer average tolerance to prone positioning (16.6 hours vs. 8.3 hours, P < 0.001 with a difference of 8.3 (4.4, 12.2) hours), higher increases in oxygen saturation postventilation (9% vs. 6%, P < 0.001 with a difference of 3.0 (1.5, 4.5)), and reduced time required for medical staff to position patients (11.7 min vs. 21.8 min, P < 0.001 with a difference of -10.1 (-11.9, -8.3)). Adverse events, including catheter displacement or blockage, facial edema, pressure injuries, and vomiting or aspiration, were markedly lower in the intervention group, with statistical significance (P < 0.05). In patients receiving combined life support, the intervention group demonstrated improved catheter blood drainage and extended CRRT filter longevity.
CONCLUSION: The newly developed adjustable prone ventilation device significantly improves tolerance to prone positioning, enhances oxygenation, and minimizes adverse events in critically ill patients, thereby also facilitating the effective application of life support technologies.
Immunotherapy plays a vital role in cancer postoperative treatment. Strategies to increase the variety of immune cells and their sustainable supply are essential to improve the therapeutic effect of immune cell-based immunotherapy. Here, inspired by tertiary lymphoid structures (TLSs), we present a microfluidic-assisted microporous annealed particle (MAP) scaffold for the persistent recruitment of diverse immune cells for cancer postoperative therapy. Based on the thermochemical responsivity of gelatin methacryloyl (GelMA), the MAP scaffold was fabricated by physical cross-linking and sequential photo-cross-linking of GelMA droplets, which were prepared by microfluidic electrospraying. Due to the encapsulation of liquid nitrogen-inactivated tumor cells and immunostimulant, the generated MAP scaffold could recruit a large number of immune cells, involving T cells, macrophages, dendritic cells, B cells, and natural killer cells, thereby forming the biomimetic TLSs in vivo. In addition, by combination of immune checkpoint inhibitors, a synergistic anticancer immune response was provoked to inhibit tumor recurrence and metastasis. These properties make the proposed MAP scaffold-based artificial TLSs of great value for efficient cancer postoperative therapy.
AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
Apatinib Mesylate Tablets(ATAN) is taken 500mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death.Treatment will be discontinued if the subject is unable to tolerate a daily dose of 500mg.
Subjects receive a small amount of F tularensis vaccine (0.0025mL) placed on a cleansed site on the skin on the volar surface of the forearm. A bifurcated needle was used to make 15 superficial punctures at the vaccination site to permit percutaneous penetration of the vaccine.
The program, Tai Chi: Moving for Better Balance, developed by ORI scientists (2003; 2004; 2008, a,b) was implemented in this dissemination project. Class duration was 90 minutes, 2-times per week over a 12-month period. During the initial 2 weeks, practice involved learning and performing 2 forms practiced in one set of 8 repetitions (for each form) and increased to a set of 10 repetitions for up to 5 forms between Week 3 and Week 5. Although additional forms were learned as the intervention progressed, starting in Week 6, training focused on 10-12 repetitions of the combination of forms rather than single forms. Once all 8 forms were learned ( Week 10), training was maintained at between 10-15 repetitions of the 8-form routine. Exercise activities were accompanied by music. Each Tai Chi practice session included (a) a 10-15 minute warm-up, (b) 60 minutes of Tai Chi practice, and (c) a 10-minute cool-down period. Instruction comprised (a) learning new movements and (b) reviewing movements learned from previous sessions. In addition, copies of the videotape/DVD and user's guidebook were distributed to all participants who were encouraged to use these materials for additional home practice.

All participating individuals were assessed at baseline, 6 months (mid-point), 12 months (intervention termination), and 6 months following the intervention (post-intervention follow-up) on measures of health, fall history, functional ability, and quality-of-life. Each evaluation session lasted about one hour and was conducted by a trained research assessor in various centers where these classes were held.
This is a single center, randomized, double-blind, placebo-controlled trial. Subjects will receive an infusion of either Angiotensin II (AngII) or a saline control (placebo) in addition to usual care with traditional vasopressors (catecholamines and vasopressin) during liver transplantation (LT). AngII is a vasopressor approved by the FDA for the treatment of vasodilatory shock. It targets the renin-angiotensin system (RAS) and has been shown to effectively raise the mean arterial blood pressure (MAP) in patients with septic shock. It also allows for lower doses of traditional vasopressors and may improve microcirculatory flow to the kidneys. The study drug will only be administered if the participants require \> 0.05 mcg/kg/min of norepinephrine while undergoing liver transplantation. The study drug will be titrated throughout the case and discontinued at the end of surgery. Randomization will be stratified based on (a) the need for renal replacement therapy preoperatively and (b) the use of normothermic machine perfusion of the liver graft.
Pitaya is a well-known fruit widely cultivated in tropical and subtropical tropical regions, and is characterized by its flesh colour into red, white, and yellow pitaya. Red pitaya has dark red flesh and is the preferred choice among consumers due to its superior taste compared to other varieties. Red pitaya has been known to cause diarrhoea, and studies have reported that pitaya does this by drawing moisture into the intestines, resulting in defecation. However, the exact mechanism of action is still unclear. In this study, mass spectrometry was employed to identify small molecular compounds in red pitaya powder, and a loperamide hydrochloride-induced early constipation mouse model was used to assess the efficacy of red pitaya. 16S rDNA and non-targeted metabolomics techniques were used to systematically reveal the regulatory characteristics of the intestinal flora and to identify the intestinal metabolites associated with constipation. The results showed that 44 novel small molecular compounds were identified from red pitaya powder, including a variety of phenolic acids and flavonoids. Pathological results showed that administration of red pitaya powder at a high dose (1000 mg kg-1) significantly ameliorated the abnormal expansion of intestinal goblet cells observed in the early stages of constipation. In addition, early constipation increased metabolites such as serotonin and 5-hydroxytryptophol, which were normalized following the ingestion of red pitaya powder. Furthermore, Erysipelatoclostridium, Parasutterella, and other abnormal gut microbiota associated with early constipation returned to healthy levels after the ingestion of red pitaya powder. Finally, significant correlations were observed between the expression of 33 different serum metabolites and the abundance of eight kinds of intestinal flora. Consequently, red pitaya holds potential as a safe food supplement for the prevention or amelioration of early-stage constipation.
Participants will receive treatment 1 in period 1 and treatment 2 in period 2. Where treatment 1= Dapagliflozin tablet 10 mg test product, treatment 2= Dapagliflozin tablet 10 mg reference product.
PURPOSE:To obtain a cutaneous amelioration agent able to readily and quite safely perform inhibition of aging and smoothing of wrinkle with also having whitening effect and rejuvenation effect by directly or mixedly using extract of rice extracted with water or an organic solvent. CONSTITUTION:Extract of rice with water or with an organic solvent is directly or mixedly used in the aimed agent. At first, rice is crushed or pulverized to more efficiently perform the extraction because of having larger surface area. Water is added to the crushed or pulverized rice in the extraction. Although the extraction with water is efficiently performed with 2-5 times amount of the adding water, the amount is suitably selected according to yield, operability and a final using object, etc. Next, the system is heated and the extraction is finished at a point of time becoming a boiling state.
Claimed is a freeze-dried biomatrix comprising 10 to 80 wt.% of natural polysaccharides and 20 to 90 wt.% modified polysaccharides. Pref., the natural polysaccharides are e.g. pectins, alginates and agar. The modified polysaccharides comprise cellulose ether derivs. and additionally spun fibres such as polyester, polyamide, polyvinyl alcohol, wool, cotton, silk and viscose. USE/ADVANTAGE - The matrix is suitable as carrier for pharmaceutical and cosmetic effective agents (0.1-20 wt.%, pref. encapsulated in liposomes), for the application of effective agents and as wound lining. Compared to collagen sponges of the prior art which are either unstable in water or which contain cross-linking agents of animal origin, the new biomatrix has the features of collagen sponges but lacks preservatives, wetting agents and perfumes. The use of only a few substances for the production of the biomatrix reduces the interaction between them during freeze drying and simplifies quality control. An improved dosage accuracy of effective agents, e.g. vitamin A-derivs., was found. Freeze drying results in a sponge like biomatrix that can easily be rehydrated and which forms a gel when moisturised. The biomatrix not contg. and spun fibres can be massaged into the skin so as to disappear completely. When the biomatrix contains spun fibres these have to be removed after, e.g. cosmetic, treatment.
An established travel-training program developed for individuals with disabilities, including those with SMI, serves as the curriculum for the public transportation intervention arm. Participants will use SEPTA, the public transportation provider in Philadelphia and surrounding areas. We will offer an 8-week intervention which will include instruction on foundational skills needed to travel on public transportation and 1-on-1 direct training in using public transportation. Participants will meet twice weekly for direct instruction and role-playing sessions to cover the core components and the latter weeks of intervention will be focused on individual travel training instruction provided by the peer support interventionists, with participants and peer support interventionists meeting for two travel trips each week.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine and is designed to evaluate the viability of myocardial tissue. Direct 13C-MR images of 13C-pyruvate and its 13C-containing metabolites of alanine, lactate and possibly bicarbonate in a subject, who the composition containing hyperpolarised 13C-pyruvate is administered beforehead. Correlation of 13C signal of metabolite with 13C signal of any other metabolite detected is conducted for acquisition the contrast based on the difference of signals intensity of two, preferably three, most preferably four 13C metabolites. ^ EFFECT: method allows to identify at-risk myocardial tissue. ^ 13 cl, 5 ex, 2 dwg
Described herein are methods for treating bone diseases or defects. The methods include administering to a host animal therapeutically effective amounts of one or more compounds that are selective inhibitors of dephosphorylation of elF2a. Osteoblasts and osteoclasts are the two major types of bone cells in bone remodeling. It has also been discovered that the compounds described herein can regulate expression of NFATd at a transcriptional level. Silencing elF2a with RNA interference reduces suppression of salubrinal/guanabenz- driven downregulation of NFATd. Thus, the compounds described herein are useful in regulating bone remodeling through elF2a-nediated signainmg for combating bone loss in osteoporosis, and related diseases